Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that aims to develop and sell products to treat central nervous system diseases. Its flagship product candidate is roluperidone, which is being developed as a treatment for schizophrenia. The company has a global licensing agreement with Mitsubishi Tanabe Pharma Corporation to distribute roluperidone, excluding Asia.